Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-690,550 withdrawal and retreatment study in moderate to severe chronic plaque psoriasis
NL-OMON36730Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tofacitinib in psoriasis, sponsored by Pfizer. Started Oct 2011; status: recruiting.
02
Drugs
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON36730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36730.